Company profile

Mitsubishi Tanabe Pharma

Diversified pharma (part of Mitsubishi Chemical Group)

Privately held: no public share price · Japan

Assets

(4 total)
4Total Assets
2Approved
2Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
AST-120(Kremezin)
Approved
Oral spherical carbon adsorbentSmall molecule
Chronic Kidney Disease
Colestilan(Cholebine / BindRen)
Approved
Phosphate binderSmall molecule
Chronic Kidney Disease
MP-513No recent activity
Phase 3
DPP-4Small molecule
Type 2 Diabetes
Teneligliptin(Tenelia)
Phase 3
DPP-4Small molecule
Type 2 Diabetes

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.